Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Experts predict a test measuring p-tau217 in blood plasma may become a standard screening tool for Alzheimer’s disease in ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech.  | Vivek Ramaswamy has found ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...